Treatment of severe ankylosing spondylitis with high-dose secukinumab: A retrospective study

Author:

Lei Hongwei1,Huang He1,Ma chenxi1,Li Yingnan1

Affiliation:

1. The Second Affiliated Hospital of Harbin Medical University

Abstract

Abstract Background: Secukinumab is an effective biological agent for the treatment of ankylosing spondylitis(AS); however, some patients do not respond well to the administration of 150 mg every 4 weeks and require more effective management measures. This retrospective study evaluates the efficacy and safety of the administration of secukinumab (300 mg every 4 weeks) in patients with severe AS. Methods: We reported 12 patients with severe ASand retrospectively reviewed their clinical records and follow-up data. These 12 patients were predominantly men (83.33%)with a mean age of 39.33 ± 13.01 years at the start of secukinumab treatment. Their mean body mass index was 27.48 ± 1.21kg/m2. The patients showed severe disease activity at baseline [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score > 4]. The protocol of administration of subcutaneous loading doses of secukinumab every 5 weeks was instituted, followed by subcutaneous administration of secukinumab, 300 mg every 4 weeks or 150 mg every 3 weeks; the patients were advised against off-label use. The assessment of the patients’ conditions, including the Ankylosing Spondylitis Disease Activity Score (ASDAS), BASDAI, and Bath Ankylosing Spondylitis Functional Index (BASFI) was performed at weeks 12 and 24. Results: All 12 patients had a reduction of more than 1.1 in the ASDAS at week 12, and the effect persisted through to week 22. The 50% BASDAIresponse rate was 58.3% at week 12 and 83.3% at week 24. No new safety findings were observed. Conclusion: Subcutaneous administration of secukinumab, 300 mg every 4 weeks or 150 mg every 3 weeks, showed sustained efficacy of AS and a consistent safety profile after 24 weeks of treatment. This study is a retrospective study with a limited number of cases and a short observation period, which were the major limitations of the study. This retrospective study provides powerful evidence for the novel treatment strategy of refractory active AS switching to 300 mg secukinumab.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3